Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

CRISPR Technique Removes HIV Genes From Live Animal Models

XTALKS VITALS NEWS

HIV

Before this breakthrough, the HIV virus proved impervious to gene editing, due to its tendency to accumulate mutations.

Share this!

May 25, 2016 | by Sarah Massey, M.Sc.

For the first time, researchers have used the CRISPR technique to successfully remove HIV genes from the genomes of animals infected with the retrovirus. Before this breakthrough, the HIV virus proved impervious to gene editing, due to its tendency to accumulate mutations.

“In a proof-of-concept study, we show that our gene editing technology can be effectively delivered to many organs of two small animal models and excise large fragments of viral DNA from the host cell genome,” said Kamel Khalili of the Comprehensive NeuroAIDS Center at Temple University. Khalili’s work is promising: using CRISPR, the viral DNA was removed from over 50 percent of the cells studied.

Khalili and his team conducted their research using mice and rats who were engineered to integrate HIV genes into every cell type. Using the precision DNA editing technique known as CRISPR, the researchers removed those HIV genes from multiple cell types, including the brain, ear, liver, kidney, lungs, spleen, and even blood. The results of the study were published in the journal, Gene Therapy.

Khalili and his team previously used the CRISPR technique in vitro to remove HIV genes from cells collected from HIV-positive patients. Now that the researchers have demonstrated the gene editing tool’s effectiveness in vivo, CRISPR could eventually be developed as a potential treatment for patients with HIV.



“If this technology gets into the clinic to treat human patients, it’s not going to be very complicated,” said Khalili. “You don’t have to bring the patient to the clinic and do a bone marrow transplant or all kinds of complicated technology. You can basically apply this to any setting.”

For now, the researchers are working on identifying the ideal dosage for the technique, and monitoring their animal models for any signs of side effects. According to Khalili and his team, the risk of off-target gene editing and other adverse events is low, because the CRISPR molecule used specifically targets HIV DNA.

“The first step is to permanently inactivate those viruses incorporated in cells,” said Khalili. “If we can do that, and reach that level, then we may be able to functionally cure individuals or have a sterilizing cure.”


Keywords: CRISPR, HIV, Gene Editing


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Exclusion Criteria for Clinical Trials Poses Major Barrier to Patient Enrollment

August 17, 2017 - UT Southwestern researchers say that clinical investigators continue to increase the number of exclusion criteria, preventing more patients from participating in clinical trials.

Featured In: Clinical Trials News


Targeting Cellular Nitrogen Metabolism Could Offer a New Treatment for Pancreatic Cancer

August 17, 2017 - An enzyme involved in regulating the amount of nitrogen in the cell could be a new drug target for pancreatic cancer, according to researchers from Boston Children's Hospital and the Broad Institute of MIT and Harvard.

Featured In: Life Science News


Regeneron’s Drug for Respiratory Syncytial Virus Fails in Phase III Clinical Trial

August 16, 2017 - Biotechnology company Regeneron has announced it will not continue development of its antibody drug, suptavumab, after a failure in a Phase III clinical trial.

Featured In: Clinical Trials News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

One Patient’s Perspective on Clinical Trials

REGISTER FOR THESE WEBINARS

Planning and Conducting Trials of the Latest Immunotherapies


ISO 13485:2016 for Medical Device Manufacturers: Ensuring a Smooth Transition through Effective Preparation


Medical Devices: Reviewing Regulatory Changes in the US and EU


Moving Beyond Regulatory and Performance Metrics in Starting Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.